# Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease

> **NCT01850381** · PHASE2 · COMPLETED · sponsor: **Genervon Biopharmaceuticals, LLC** · enrollment: 6 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** GM608
- **DRUG:** Placebo Comparator

## Key facts

- **NCT ID:** NCT01850381
- **Lead sponsor:** Genervon Biopharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2019-08-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01850381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01850381, "Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01850381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*